Sunshine Revenue Per Share from 2010 to 2025

SBFMW Stock  USD 0.19  0.03  18.75%   
Sunshine Biopharma Revenue Per Share yearly trend continues to be fairly stable with very little volatility. Revenue Per Share is likely to outpace its year average in 2025. Revenue Per Share is the amount of revenue generated by Sunshine Biopharma Warrant per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
1.8 K
Current Value
1.9 K
Quarterly Volatility
742.58340152
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of Sunshine Biopharma Warrant over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Sunshine Biopharma's Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 197.4210 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

Sunshine Revenue Per Share Regression Statistics

Arithmetic Mean410.70
Geometric Mean25.51
Coefficient Of Variation180.81
Mean Deviation570.53
Median29.36
Standard Deviation742.58
Sample Variance551,430
Range2K
R-Value0.75
Mean Square Error257,190
R-Squared0.56
Significance0.0008
Slope117.21
Total Sum of Squares8.3M

Sunshine Revenue Per Share History

2025 1871.57
2024 1782.45
2023 1980.5
2022 572.54
2021 174.91
2020 82.46
2019 11.97

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share1.8 K1.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.